Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer

Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer

The aim of this study was to determine the efficacy and safety of apatinib combined with S-1 on advanced pancreatic cancer patients after failure of first-line chemotherapy.

1. To observe the curative efficacy of apatinib and S-1 on patients by analyzing the data of overall survival (OS), complete remission (CR) or partial remission (PR), the rate of progression free survival (PFS), levels of CA19-9 and VEGFR in serum [Time Frame: Evaluation at 2 month intervals through study completion from the date of study entry until the date of progression, up to 1 year].
2. To observe any adverse events, including abnormal clinical symptoms and vital signs, abnormal laboratory examinations, and to record the clinical features, severity, occurrence time, duration, management and prognosis of all subjects during the clinical study, and to determine the correlation between these adverse events and the experimental drugs. . The safety of drugs used in advanced pancreatic cancer was evaluated by CTCAE v4.0

Inclusion criteria:

• 18-70 years old;

• ECOG score: 0-2;

• Have confirmed metastatic or locally advanced unresectable pancreatic cancer;

• At least one measurable lesion according to the RECIST1.1 standard;

• First-line chemotherapy drugs do not include S-1 or fluorouracil drugs;

• Main organ functions meet the following standards:

  • Baseline blood routine (the inspection standard should meet the requirements of no blood transfusion and blood products within 14 days, no use of G-CSF and other hematopoietic stimulant correction) :

    • Hemoglobin>80g/L
    • The absolute neutrophil count (ANC) 1.5 x 109 / L;
    • Blood platelet (PLT)> 90 x 109 / L;

  • Baseline biochemical test shall meet the following standards:

    • T BIL < 1.5*ULN.
    • A LT and AST<2.5*ULN, and in patients with liver metastasis < 5*ULN;
    • Cr≤1.5*ULN.
    • Albumin is greater than or equal to 30g/L;

• Women of child-bearing age must already have access to reliable contraception. Pregnancy tests (serum or urine) were performed within 7 days prior to enrollment and the results were negative, and a reliable method of contraception was preferred 8 weeks after the trial period and the last drug administration;

• Subjects will voluntarily join the study and sign the informed consent.

Exclusion criteria:

• Clearly allergic to apatinib, S-1 or their excipients;

• There are various factors affecting oral drugs (including dysphagia, chronic diarrhea, intestinal obstruction, etc.);

• Serious heart diseases in the last six months, including :

  • angina;
  • myocardial infarction;
  • heart failure;
  • interphase of QTc >450ms;
  • any other heart diseases that were judged as unsuitable for the study;

• Combined with uncontrollable hypertension after drug treatment (systolic blood pressure >140mmHg, diastolic blood pressure >90mmHg);

• Complicated with other serious medical diseases, including cerebrovascular disease, uncontrolled infection, active peptic ulcer, intestinal obstruction, etc.;

• Metastasis of tumor central nervous system;

• Women during pregnancy and lactation;

• The patient has been diagnosed with other tumors in the past five years, except for the following situations: B. Cured basal cell carcinoma of the skin and cured orthotopic carcinoma of the cervix;

• The time from the last chemotherapy is shorter than 4 weeks or 5 half-life (the time taken is older), and the time from the last radiotherapy is shorter than 4 weeks;

• Use the experimental drug within 28 days before enrollment;

• Patients with grade 2 or above toxicity caused by the use of anti-tumor drugs before enrollment;

• Have mental disorders or a history of substance abuse;

• Other circumstances that the investigator deems inappropriate to participate in the study;